SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Revenue showed a marginal decline at Rs. 0.00 millions. For the quarter ended September 2023, as compared to corresponding quarter of last year.The Net Loss for the quarter ended September 2023 is Rs. -49.17 millions as compared to Net Loss of Rs. -30.83 millions of corresponding quarter ended September 2022 Operating profit Margin for the quarter ended September 2023 further decreased to -45.24% as compared to -21.81% of corresponding quarter ended September 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 0.00 264.80 0.00 0.00 369.59 0.00 446.09 783.88 -43.09
Other Income 1.64 3.20 -48.75 2.66 4.64 -42.67 28.03 11.02 154.36
PBIDT -45.24 -21.81 107.43 -87.35 -68.67 27.20 -156.64 -38.84 303.30
Interest 20.87 17.42 19.80 38.08 33.22 14.63 70.41 55.92 25.91
PBDT -66.11 -39.23 68.52 -125.43 -101.89 23.10 -227.05 -94.76 139.61
Depreciation 0.34 0.36 -5.56 0.68 0.73 -6.85 1.46 2.13 -31.46
PBT -66.45 -39.59 67.85 -126.11 -102.62 22.89 -228.51 -96.89 135.84
TAX -17.28 -8.76 97.26 -31.08 -21.83 42.37 -57.95 -9.34 520.45
Deferred Tax -17.28 -8.76 97.26 -31.08 -21.83 42.37 -57.95 -9.34 520.45
PAT -49.17 -30.83 59.49 -95.03 -80.79 17.63 -170.56 -87.55 94.81
Equity 431.80 431.80 0.00 431.80 431.80 0.00 431.80 431.80 0.00
PBIDTM(%) 0.00 -8.24 0.00 0.00 -18.58 0.00 -35.11 -4.95 608.69

Bharat Immunological Share Price

16.86 -0.21 (-1.23%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×